News

The CEO and co-founder of Theranica discussed the migraine treatment device’s mechanism of action and its successes in reducing medication overuse headache.

The professor of neurology at University Medical Center Schleswig‐Holstein, and member of the department of neurodegenerative diseases at University Hospital Tübingen shared insight into the quantitative gait characteristics measured by wearable devices which can play an important role in the identification of prodromal Parkinson disease and its progression.

The findings demonstrated that the galcanezumab group—made up of those with both chronic and episodic migraine—experienced a 4.1-day reduction in monthly migraine headache days compared to a 1.0-day reduction with placebo.

The clinical neuropsychologist and head of the School of Psychological Sciences at the University of Melbourne detailed how the transition from states of illness to wellness after epilepsy surgery can result not just in brain changes, but psychosocial challenges for patients.

Mind Moments® a podcast from NeurologyLive®, brings you exclusive interviews with experts in neurologic disorders.

The staff neurologist at Cleveland Clinic’s Mellen Center for MS shared her insight into the use of telemedicine in an outpatient setting across a number of subspecialties in neurology and how it can supplement care going forward.

Interim data from the first 8 pediatric patients showed that the AAV-CLN6 gene therapy demonstrated a positive impact on motor and language function compared to a natural history dataset, as well as in comparison to in-study sibling pairs.

Neurology News Network for the week ending August 3, 2019.

The director of the Pediatric Stroke Program at CHOP spoke about the need to improve early recognition of pediatric stroke and physician awareness of the condition, which many believe is underdiagnosed and underestimated.

The program director of neurology at the Zucker School of Medicine, Northwell Health, spoke about the great advances of the new CGRP medications available for the prevention of migraine.

The clinical neuropsychologist and head of the School of Psychological Sciences at the University of Melbourne spoke about what physicians need to provide to help patients through the adjustment period after epilepsy surgery.

Patients who received diroximel fumarate experienced statistically significantly fewer number of days of key gastrointestinal symptoms with intensity scores ≥2 on the IGISIS compared to those on dimethyl fumarate.

The FDA has assigned the application a PDUFA target action date of March 17, 2020.

The clinical neuropsychologist and head of the School of Psychological Sciences at the University of Melbourne discussed the early-stage research into neurorehabilitation post-epilepsy surgery, and the promise it might hold to address surgery’s long-term risks.

One year post-launch, the Ambry Genetics and Akcea Therapeutics hereditary ATTR amyloidosis testing program has been used by more than 700 physicians. The free test screens for up to 81 genes that cause hereditary polyneuropathies and up to 92 genes associated with hereditary cardiomyopathies, including hATTR amyloidosis.

After its recent FDA clearance, the smartphone-controlled Nerivio Migra makes its entrance into the market in the fall. Theranica’s CEO and co-founder spoke to its clinical efficacy and advantages for patients and physicians.

On our anniversary, take a look back at some of our most popular articles and interviews across a range of neurology topics.

Early focal inflammatory disease activity and spinal cord lesions are predictors of long-term disease outcomes, which may be useful in counseling patients and personalizing treatment plans.

At usual-speed walking, a number of domains of gait variability, pace, asymmetry, and postural control were significantly predictive of conversion to Parkinson disease, and could be used in combination with markers to identify prodromal disease and its progression.

Investigators found reductions in tic frequency and increases in the number of tic-free intervals when children were merely asked verbally to suppress their tics, and when an immediate and contingent reward was delivered for successful tic suppression, tic suppression was enhanced.

The director of the Jefferson Comprehensive Epilepsy Center discussed what’s currently being developed in the treatment of epilepsy, as well as the emergence of different methods of stimulation and neuromodulation.

The use of single-pulse transcranial magnetic stimulation, while already FDA-approved for acute and preventive migraine treatment, has shown that it can be effective in reducing the need for acute headache medications in patients with migraine.

The clinical professor of neurology at Albert Einstein College of Medicine spoke to the findings of the OVERCOME study, and how recent literature has suggested that improper prescriptions and medication use in migraine have been ongoing in spite of the current recommendations.

Zogenix has announced that its Study 1601 of fenfluramine (Fintepla), also known as ZX008, in the treatment of seizures associated with Lennox-Gastaut syndrome has completed enrollment and is on schedule to report top-line data in Q1 2020.

Despite the fact that the rate of reductions for recurrent stroke in the intensive group were not significant in this study, a meta-analysis of 3 previous trials supports the use of a blood pressure target less than 130/80 mm Hg to reduce stroke recurrence.

The co-director of the University of Pennsylvania Memory Center will share additional insights on Alzheimer disease at the upcoming International Congress on the Future of Neurology, taking place September 27-28, 2019 in New York City.

The director of the MedStar Georgetown Headache Center discussed the barriers to patient and clinician education in migraine and the gap in available interventions for the diverse patient population.

The University of Alabama at Birmingham neuromodulation epilepsy clinic has treated 43 patients with drug-resistant epilepsy, reducing seizures by >60% for a number of patients with both vagus nerve stimulation and responsive neurostimulation techniques.